Challenges of recurrent hepatitis C in the liver transplant patient.
Cirrhosis secondary to hepatitis C virus (HCV) is a very common indication for liver transplant. Unfortunately recurrence of HCV is almost universal in patients who are viremic at the time of transplant. The progression of fibrosis has been shown to be more rapid in the post-transplant patients than in the transplant naïve, hence treatment of recurrent HCV needs to be considered for all patients with documented recurrent HCV. Management of recurrent HCV is a challenging situation both for patients and physicians due to multiple reasons as discussed in this review. The standard HCV treatment with pegylated interferon and Ribavarin can be considered in these patients but it leads to a lower rate of sustained virologic clearance than in the non-transplanted population. Some of the main challenges associated with treating recurrent HCV in post-transplant patients include the presence of cytopenias; need to monitor drug-drug interactions and the increased incidence of renal compromise. In spite of these obstacles all patients with recurrent HCV should be considered for treatment since it is associated with improvement in survival and a delay in fibrosis progression. With the arrival of direct acting antiviral drugs there is renewed hope for better outcomes in the treatment of post-transplant HCV recurrence. This review evaluates current literature on this topic and identifies challenges associated with the management of post-transplant HCV recurrence.
Renumathy Dhanasekaran, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55901, United States.
Renumathy
R
Dhanasekaran
Renumathy Dhanasekaran, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55901, United States.
Roberto J
RJ
Firpi
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D065095:Calcineurin Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018450:Disease Progression; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications / Q000473:pathology* / Q000628:therapy*; D016031:Liver Transplantation; D011110:Polymorphism, Genetic; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D065095:Calcineurin Inhibitors; D007372:Interferons
Cirrhosis; Hepatitis C; Interferon; Recurrence; Transplant